Legal & General Group PLC Oric Pharmaceuticals, Inc. Transaction History

Legal & General Group PLC

$440 Billion
Q2 2024

A detailed history of Legal & General Group PLC transactions in Oric Pharmaceuticals, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 37,972 shares of ORIC stock, worth $404,401. This represents 0.0% of its overall portfolio holdings.

Number of Shares

37,972

Previous 3,253 1067.29%

Holding current value

$404,401

Previous $44,000 509.09%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$6.63 - $12.93 $230,186 - $448,916	34,719 Added 1067.29%	37,972 $268,000
Q3 2023 Nov 14, 2023	SELL	$6.05 - $9.28 $3,031 - $4,649	-501 Reduced 13.35%	3,253 $19,000
Q2 2023 Aug 14, 2023	BUY	$4.95 - $8.4 $18,582 - $31,533	3,754 New	3,754 $29,000
Q3 2022 Nov 14, 2022	SELL	$3.15 - $5.24 $7,969 - $13,257	-2,530 Closed	0 $0
Q2 2022 Aug 22, 2022	SELL	$2.7 - $7.07 $19,105 - $50,027	-7,076 Reduced 73.66%	2,530 $11,000
Q4 2021 Feb 14, 2022	BUY	$12.01 - $20.3 $6,725 - $11,368	560 Added 6.19%	9,606 $142,000
Q3 2021 Nov 15, 2021	BUY	$15.9 - $25.22 $77,735 - $123,300	4,889 Added 117.61%	9,046 $189,000
Q2 2021 Aug 12, 2021	SELL	$17.37 - $25.34 $5,992 - $8,742	-345 Reduced 7.66%	4,157 $74,000
Q1 2021 May 17, 2021	BUY	$23.67 - $36.85 $29,824 - $46,431	1,260 Added 38.86%	4,502 $110,000
Q4 2020 Feb 12, 2021	BUY	$20.32 - $39.8 $44,094 - $86,366	2,170 Added 202.43%	3,242 $110,000
Q3 2020 Nov 13, 2020	SELL	$19.5 - $31.26 $6,630 - $10,628	-340 Reduced 24.08%	1,072 $27,000
Q2 2020 Aug 14, 2020	BUY	$25.68 - $38.12 $36,260 - $53,825	1,412 New	1,412 $47,000

Others Institutions Holding ORIC

# of Institutions

112

Shares Held

63.1M

Call Options Held

Put Options Held

View Full List

About Oric Pharmaceuticals, Inc.

Ticker ORIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,576,700
Market Cap $421M
Description
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...

More about ORIC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Oric Pharmaceuticals, Inc. Transaction History